Mural Oncology PLC — Director's Dealing 2025

Dec 5, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Mural Oncology plc (MURA)
CIK: 0001971543
Period of Report: 2025-12-05

Reporting Person: Loew Caroline (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-12-05	Ordinary Shares	D	293059	—	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-12-05	Stock Option (right to buy)	$5.4809	D	379690	Disposed	2033-07-02	Ordinary Shares (379690)	Direct
2025-12-05	Stock Option (right to buy)	$5.39	D	90025	Disposed	2034-02-28	Ordinary Shares (90025)	Direct
2025-12-05	Stock Option (right to buy)	$3.43	D	134225	Disposed	2035-03-02	Ordinary Shares (134225)	Direct

Footnotes

F1: Pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"), as of December 5, 2025 (the "Effective Time").

F2: Includes the disposition of 220,148 unvested restricted stock units ("RSUs"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically cancelled and converted into the right to receive an amount equal to the Scheme Consideration.

F3: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options.